CME GROUP INC.
In the published model solve dated 2026-Q2, anchored at $285.40, CME GROUP INC. (CME) is priced for +10.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Almost two thirds of every revenue dollar reaches operating income, a 66.9% margin earned by owning the venue and the clearing house rather than by taking any position in the markets that run through them. • The concentration is in what makes contracts trade, not in any single customer: interest rate products are about 26% of revenue, and the FY2025 annual report lists ⟦"changes in government monetary policies and the U.S. Federal Reserve and other international banks' forecasted interest rat
Is CME overvalued? See what's priced in →
1,741 institutional managers reported holding CME in 13F filings for the quarter ended 2026-03-31. Together they hold about 85% of the company; the top 10 hold 35%. 157 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 5.2M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (1.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CME's share count is about flat over the past five years. It pays a dividend, and has paid one every year in our records (18 and counting), raised 6 years straight; the current rate is $5.00 a share annually. Cash returned over the past three years: $11.01B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CME over the trailing three years: 2023: 4 buys totaling $117k; 2024: 10 buys totaling $536k; 2025: 10 buys totaling $616k; 2026: 3 buys totaling $515k. 32 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CME's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +3.9% | +2.3% |
| 2023-11-02 | +0.6% | -4.6% |
| 2024-02-29 | +1.7% | -5.8% |
| 2024-05-02 | -0.8% | -5.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CME's latest 8-K filings: 2026-08-11 (items 7.01, 9.01); 2026-07-22 (items 2.02, 9.01); 2026-06-17 (items 5.02, 7.01, 9.01); 2026-06-10 (items 5.07); 2026-05-19 (items 5.07).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.